Natco Pharma Ltd. Financials: Quarterly Results
Revenue
705.4
Cr.
PAT
140.40
Cr.
EBITDA
170.60
Cr.
Natco Pharma Ltd. Q3FY26 Financial Metrics
| Indicator | Dec-25 | Sep-25 | Jun-25 | Mar-25 | Dec-24 |
|---|---|---|---|---|---|
| Net Sales/Income from operations (Cr.) | 647.30 | 1363 | 1328.90 | 1221 | 474.80 |
| Total Income From Operations (Cr.) | 647.30 | 1363 | 1328.90 | 1221 | 474.80 |
| P/L Before Interest, Excpt. Items & Tax (Cr.) | 170.60 | 626.80 | 575.10 | 516.10 | 168.10 |
| P/L Before Exceptional Items & Tax (Cr.) | 161.10 | 613.70 | 571.90 | 505.90 | 163.70 |
| P/L After Tax from Ordinary Activities (Cr.) | 140.40 | 517.90 | 480.30 | 406 | 132.40 |
| Net Profit/Loss For the Period (Cr.) | 140.40 | 517.90 | 480.30 | 406 | 132.40 |
| Basic EPS | 8.46 | 28.94 | 26.84 | 22.70 | 7.43 |
FAQs
Natco Pharma Ltd. announced its quarterly results for Q3 FY2026 on February 12, 2026.
In Q3 FY2026, Natco Pharma Ltd. are as follows:
Revenue: ₹705.4 crore
Net Profit: ₹140.40 crore.
For Q3 FY2026, Natco Pharma Ltd. posted ₹705.4 crore in revenue and ₹140.40 crore in net profit.
Past quarterly results for Natco Pharma Ltd. can be found on their official Investor Relations page, which includes detailed reports and financial performance summaries.